Fig. 8.
Intrathecal administration of 5-HT2C receptor antagonist RS-102221 blocked VPA’s inhibition on visceral hypersensitivity. Intrathecal administration of DMSO (vehicle of RS-102221) and systemic administration of VPA did not change the magnitude of VMR to colorectal distention post FS. 5-HT2C receptor antagonist RS-102221 blocked the anti-hypersensitivity effect of VPA at day 2 post FS, but the effect vanished at day 6 post FS. ** P < 0.01 vs baseline.